ライフサイエンスコーパス: Gy

1 A 1.0 Gy increase in mean, median, and D(70) absorbed dose was

2 , and kidneys were 7.1, 10.3, 15.0, and 22.0 Gy per MBq/mL.

3 assignment 1:1 between standard RT dose 68.0 Gy to the primary tumor or dose escalation to 73.1 Gy.

4 ere significantly weaker than those in the 0-Gy group.

5 l radiation, those who had received <= 32.00 Gy were at no higher risk, unlike those who had received

6 risk, unlike those who had received > 32.00 Gy.

7 08/Gy; p < 0.001) and ACM (adjusted HR: 1.02/Gy; 95% CI: 1.00 to 1.03/Gy; p = 0.007).

8 sured by the calorimeter ranged between 0.03 Gy/pulse and 5.26 Gy/pulse, corresponding to collection

9 (adjusted HR: 1.02/Gy; 95% CI: 1.00 to 1.03/Gy; p = 0.007).

10 QR: 0.07-0.13), and 0.028 (IQR: 0.026-0.034) Gy/GBq, respectively.

11 09 Gy/MBq) and to bone marrow (0.31 +/- 0.05 Gy/MBq).

12 sk of MACE (adjusted hazard ratio [HR]: 1.05/Gy; 95% CI: 1.02 to 1.08/Gy; p < 0.001) and ACM (adjuste

13 bed doses of 2.04 +/- 0.32 and 1.68 +/- 0.06 Gy/MBq to 4T07 and 4T1 tumors, respectively, which were

14 rd ratio [HR]: 1.05/Gy; 95% CI: 1.02 to 1.08/Gy; p < 0.001) and ACM (adjusted HR: 1.02/Gy; 95% CI: 1.

15 than those delivered to liver (1.28 +/- 0.09 Gy/MBq) and to bone marrow (0.31 +/- 0.05 Gy/MBq).

16 dose to the kidney per cycle was 5.3 +/- 2.1 Gy (0.81 +/- 0.32 Gy/GBq).

17 ranging from 3.0-6.6 Gy (cortex) and 2.7-5.1 Gy (medulla).

18 bed doses of 3.0-6.6 Gy (cortex) and 2.7-5.1 Gy (medulla).

19 the primary tumor or dose escalation to 73.1 Gy.

20 ainst experimental data for irradiated (0-10 Gy) and/or heated (0-240 CEM(43)) HCT116 spheroids.

21 3 fold) in mouse serum on day 1 after 0.5-10 Gy TBI.

22 re was also carried out using 0, 1, 5 and 10 Gy gamma radiation.

23 followed by a single radiotherapy dose of 10 Gy (groups 2-3) or sham irradiation (group 1) 30 min lat

24 ficant differences at an absorbed dose of 10 Gy, both in terms of decreased mortality and fertility.

25 sposition gene mutations, chest radiation 10 Gy or greater, or both.

26 In contrast, high dose radiation (10 Gy and above) decreases miR-15a and increases SMPD1.

27 ) and mean lung radiation of greater than 10 Gy (15.6, 2.6-92.7).

28 ients receiving a tumor dose of less than 10 Gy, only one achieved a PSA response of at least 50%.

29 onance imaging for survivors treated with 10 Gy or greater chest radiation (strong recommendation) an

30 n that very high dose rate radiation (35-100 Gy/second) referred to as FLASH tends to spare the norma

31 diosurgery with single large doses of 40-100 Gy to 5-7.5 mm fields in the left primary motor cortex a

32 lesions were seen in the grey matter at 100 Gy and in white matter at 60 Gy.

33 Participants who received at least 100 Gy (n = 67) had longer survival than those who received

34 rvival than those who received less than 100 Gy (median, 14.1 months [95% CI: 9.6 months, 18.6 months

35 ng a tumor dose greater than or equal to 100 Gy (best cut-off according to the receiver operating cha

36 n-absorbed dose greater than or equal to 100 Gy and optimal agreement.

37 median tumor radiation-absorbed dose was 112 Gy (IQR: 68-220 Gy).

38 ) and patients with progressive disease (116 Gy; 95% CI, 81-165 Gy; n = 9) (P = 0.01).

39 mplete response and progressive disease (117 Gy; 95% CI, 87-159 Gy; n = 21) (P = 0.0008).

40 loablative conditioning with fractionated 12 Gy TBI and etoposide versus fludarabine, thiotepa, and e

41 The apical dose was 100 to 120 Gy aiming to deliver >=250 Gy to the sclera.

42 those with progressive disease (median, 121 Gy [IQR: 86-190 Gy] vs 85 Gy [IQR: 58-164 Gy]; P = .02).

43 178-303 Gy; n = 32) and stable disease (147 Gy; 95% CI, 113-191 Gy; n = 28) (P = 0.01) and between c

44 n the blood serum of wild-type mice after 15 Gy radiation dose, inducing a gastrointestinal syndrome.

45 With RT alone (15 Gy, single dose), all animals died by 72 days; INP pretr

46 Irradiation of >= 7 vertebrae (>= 15 Gy on >= 90% of their volume) without pituitary irradiat

47 or >= 35 Gy or both >= 100 mg/m(2) and >= 15 Gy]).

48 ose of 1-99 mg/m(2) and/or radiotherapy < 15 Gy], moderate [100 to < 250 mg/m(2) or 15 to < 35 Gy], o

49 and mean kidney radiation of greater than 15 Gy (>15-20 Gy, 3.6 [1.5-8.5]; >20 Gy 4.6 [1.1-19.6]); fo

50 irradiation (90 keV, 9 mA) to doses up to 15 Gy.

51 progressive disease (117 Gy; 95% CI, 87-159 Gy; n = 21) (P = 0.0008).

52 21 Gy [IQR: 86-190 Gy] vs 85 Gy [IQR: 58-164 Gy]; P = .02).

53 progressive disease (116 Gy; 95% CI, 81-165 Gy; n = 9) (P = 0.01).

54 ultiple microbleeds compared to a dose of 18 Gy.

55 Per 1/2 mutant) circadian conditions with 18 Gy of IR to the heart.

56 ibed moderate-dose chest radiation (10 to 19 Gy), radiation dose-volume, anthracyclines and alkylatin

57 ressive disease (median, 121 Gy [IQR: 86-190 Gy] vs 85 Gy [IQR: 58-164 Gy]; P = .02).

58 and stable disease (147 Gy; 95% CI, 113-191 Gy; n = 28) (P = 0.01) and between complete response and

59 ate irradiations at dose rates of 0.1 to 1.2 Gy/day.

60 determined to be 11.0, 12.1, 13.6, and 15.2 Gy per MBq/mL at image times of 24, 48, 72, and 96 h, re

61 determined to be 11.0, 12.1, 13.6, and 15.2 Gy per MBq/mL at image times of 24, 48, 72, and 96 hours

62 lete or partial response to IC received 61.2 Gy to the nasopharynx and neck, and patients with stable

63 IMRT (76 Gy in 38 fractions) or H-IMRT (70.2 Gy in 26 fractions).

64 d patients with stable disease received 71.2 Gy.

65 Hindlimb-targeted irradiation (3 x 8.2 Gy) of 4-week-old mice successfully eliminated RMS tumor

66 samples by dose categories below or above 2 Gy up to 8 days after total body exposure.

67 he red marrow and the kidneys (BED(max) of 2 Gy(15) and 40 Gy(2.5), respectively) were assumed to be

68 e conditioned with CD45-SAP, CD45-SAP plus 2 Gy of total body irradiation (TBI), 2 Gy of TBI, 8 Gy of

69 Standard low dose radiation (2 Gy) upregulates miR-15a and decreases SMPD1 levels.

70 form transplantation conditioning regimen (2 Gy of total-body irradiation, cyclophosphamide, and flud

71 plus 2 Gy of total body irradiation (TBI), 2 Gy of TBI, 8 Gy of TBI, or no conditioning and treated b

72 intracranial cancer, defined as within the 2 Gy isodose line.

73 ery 3 or 4 days starting 3 days before 3 x 2 Gy or 4 x 0.5 Gy whole-body or tumor-focused radiation.

74 nd combination treatments of radiation (0-20 Gy), and hyperthermia at 47 degrees C (0-780 CEM(43)) ha

75 dney radiation of greater than 15 Gy (>15-20 Gy, 3.6 [1.5-8.5]; >20 Gy 4.6 [1.1-19.6]); for heart tra

76 4.61 to 9.86]), pituitary irradiation (5-20 Gy: RR, 4.24 [95% CI, 1.98 to 9.06]; 20-40 Gy: RR, 10.16

77 Using a single dose (20 Gy) of radiation to the oral cavity of female C57BL/6 J

78 er than 15 Gy (>15-20 Gy, 3.6 [1.5-8.5]; >20 Gy 4.6 [1.1-19.6]); for heart transplantation, anthracyc

79 pecially among survivors with chest RT >= 20 Gy (RR, 4.4; 95% CI, 1.6 to 12.4), or with a cumulative

80 ceived a single dose of 0, 11, 14, 17, or 20 Gy irradiation (the 20 Gy group was not used because 50%

81 ats received radiation doses of 0, 10, or 20 Gy to the abdominal wall and underwent laparotomy 4 week

82 and mean heart radiation of greater than 20 Gy (dose-dependent, both p<0.0001); for liver transplant

83 0, 11, 14, 17, or 20 Gy irradiation (the 20 Gy group was not used because 50% died).

84 randomly selected orbit was treated with 20 Gy of external beam therapy; sham therapy was given to t

85 were treated with chest radiotherapy with 20 Gy or greater, age 25 to 50 years, and without breast im

86 nd ultimate tensile strength (UTS) in the 20-Gy group were significantly weaker than those in the 0-G

87 al control after HDT, local radiotherapy (21 Gy), and immunotherapy.

88 ients with complete or partial response (210 Gy; 95% CI, 161-274 Gy; n = 13) and patients with progre

89 iation-absorbed dose was 112 Gy (IQR: 68-220 Gy).

90 ose was found between complete response (232 Gy; 95% confidence interval [CI], 178-303 Gy; n = 32) an

91 Radiation dose of 24 Gy conveyed a 5-fold greater risk (95% CI 2.57-10.32) of

92 a randomized clinical trial, showing that 24 Gy SDRT, but not 3x9 Gy fractionation, coupled early tum

93 ly) or stereotactic body radiotherapy (36.25 Gy in five fractions over 1-2 weeks).

94 erwent 5 total SBRT therapy sessions with 25-Gy single-fraction dose delivered to the area of culprit

95 se was 100 to 120 Gy aiming to deliver >=250 Gy to the sclera.

96 26 Gy in five fractions over 1 week is non-inferior to the

97 imeter ranged between 0.03 Gy/pulse and 5.26 Gy/pulse, corresponding to collection efficiencies betwe

98 5 27 Gy patients, and 121 of 1020 (11.9%) 26 Gy patients.

99 15 fractions) and -0.7% (-1.3 to 0.3) for 26 Gy in five fractions (p=0.00019 vs 40 Gy in 15 fractions

100 tions and 1.12 (0.94 to 1.34, p=0.20) for 26 Gy in five fractions.

101 ive fractions and 0.67 (0.38 to 1.16) for 26 Gy in five fractions.

102 t risk for 27 Gy versus 40 Gy but not for 26 Gy versus 40 Gy.

103 27 Gy in five fractions (over 1 week), or 26 Gy in five fractions (over 1 week) to the whole breast o

104 The volume of the ciliary body receiving 26 Gy was the only variable associated with the risk of cat

105 oup, 27 in the 27 Gy group, and 21 in the 26 Gy group); HRs versus 40 Gy in 15 fractions were 0.86 (9

106 67 to the 27 Gy schedule, and 1368 to the 26 Gy schedule.

107 9.9%) 40 Gy patients, 155 (15.4%) of 1005 27 Gy patients, and 121 of 1020 (11.9%) 26 Gy patients.

108 15 fractions were -0.3% (-1.0 to 0.9) for 27 Gy in five fractions (probability of incorrectly accepti

109 tions were 0.86 (95% CI 0.51 to 1.44) for 27 Gy in five fractions and 0.67 (0.38 to 1.16) for 26 Gy i

110 1.55 (95% CI 1.32 to 1.83, p<0.0001) for 27 Gy in five fractions and 1.12 (0.94 to 1.34, p=0.20) for

111 owed higher normal tissue effect risk for 27 Gy versus 40 Gy but not for 26 Gy versus 40 Gy.

112 atients (31 in the 40 Gy group, 27 in the 27 Gy group, and 21 in the 26 Gy group); HRs versus 40 Gy i

113 signed to the 40 Gy schedule, 1367 to the 27 Gy schedule, and 1368 to the 26 Gy schedule.

114 her 40 Gy in 15 fractions (over 3 weeks), 27 Gy in five fractions (over 1 week), or 26 Gy in five fra

115 or partial response (210 Gy; 95% CI, 161-274 Gy; n = 13) and patients with progressive disease (116 G

116 1.5 to 3.9 Gy), giving a 5-fr schedule of 28 Gy (95% CI, 26 to 30 Gy) estimated to be isoeffective wi

117 The mean marginal dose was 12.3 Gy +/- 0.6 (range 11-13.5).

118 gland factors were 6.7, 9.4, 13.3, and 19.3 Gy per MBq/mL at those times, and kidneys were 7.1, 10.3

119 l radiotherapy (e.g., 30-40 fractions of 2-3 Gy daily X-ray dose delivered over several weeks for loc

120 underwent radiation treatment 30-42 Gy in 3 Gy/fraction regimens to surgical cavity were retrospecti

121 of neutrons and X-rays to a total dose of 3 Gy.

122 nsisted of fludarabine (90 mg/m2) and 2 to 3 Gy total body irradiation.

123 4; 28.5 Gy: 4) and 96 deaths (50 Gy: 30; 30 Gy: 33; 28.5 Gy: 33) have occurred.

124 silateral breast cancer events (50 Gy: 3; 30 Gy: 4; 28.5 Gy: 4) and 96 deaths (50 Gy: 30; 30 Gy: 33;

125 th 50 Gy/25 fr, but NTE were higher after 30 Gy/5 fr.

126 al breast tumor recurrence (IBTR) between 30 Gy in 5 once-daily fractions (APBI arm) and 50 Gy in 25

127 1.64 (95% CI, 1.08 to 2.49; P = .019) for 30 Gy and 1.10 (95% CI, 0.70 to 1.71; P = .686) for 28.5 Gy

128 2.12 (95% CI, 1.55 to 2.89; P < .001) for 30 Gy and 1.22 (95% CI, 0.87 to 1.72; P = .248) for 28.5 Gy

129 cancer for those treated with neck RT >= 30 Gy (RR, 12.9; 95% CI, 1.6 to 46.6) with marginal statist

130 given partial brain irradiation of 10 or 30 Gy integral dose using 100 MeV protons configured either

131 g a 5-fr schedule of 28 Gy (95% CI, 26 to 30 Gy) estimated to be isoeffective with 50 Gy/25 fr.

132 32 Gy; 95% confidence interval [CI], 178-303 Gy; n = 32) and stable disease (147 Gy; 95% CI, 113-191

133 per cycle was 5.3 +/- 2.1 Gy (0.81 +/- 0.32 Gy/GBq).

134 es of 2.72 +/- 0.33 Gy/MBq and 2.67 +/- 0.32 Gy/MBq, respectively.

135 .992 Gy for all patients (range, 0.431-2.323 Gy).

136 ded to tumor dose estimates of 2.72 +/- 0.33 Gy/MBq and 2.67 +/- 0.32 Gy/MBq, respectively.

137 ans from age 15 to 40 years ranged from 0.34 Gy (5th-95th percentiles, 0.18-0.75; dual-energy VNC CT)

138 the tumour bed, and APBI was delivered as 34 Gy of brachytherapy or 38.5 Gy of external bream radiati

139 5% CI, 1.20 to 1.76), pelvic radiation >= 34 Gy (PR, 1.46; 95% CI, 1.01 to 2.11), and lung surgery (P

140 to cranial radiation, pelvic radiation >= 34 Gy, abdominal radiation > 40 Gy, cisplatin >= 600 mg/m(2

141 o < 35 Gy], or high [>= 250 mg/m(2) or >= 35 Gy or both >= 100 mg/m(2) and >= 15 Gy]).

142 moderate [100 to < 250 mg/m(2) or 15 to < 35 Gy], or high [>= 250 mg/m(2) or >= 35 Gy or both >= 100

143 ents to assess if ultra-high dose rate of 35 Gy/second can spare the immune system in models of radia

144 median dose of cRT was 30.6 Gy (range, 24-36 Gy).

145 gross residual tumor, for a total dose of 36 Gy.

146 nodal levels with extranodal extension to 36 Gy in 1.8-Gy fractions twice per day.

147 e de-escalation from 60 to 66 Gy to 30 to 36 Gy of adjuvant radiotherapy (RT) for selected patients w

148 tressors: CIR (long-duration growth under 36 Gy/h) and acute (10 kGy/h) ionizing radiation (IR), heav

149 maximal kidney biologic effective dose of 37 Gy.

150 The median parenchyma-absorbed dose was 37 Gy (range, 12-55 Gy).

151 trial, showing that 24 Gy SDRT, but not 3x9 Gy fractionation, coupled early tumor ischemia/reperfusi

152 gical resection, an additional boost of 14.4 Gy was delivered to the gross residual tumor, for a tota

153 mcitabine, the second combined with 15 x 2.4 Gy radiotherapy, followed by surgery and 4 courses of ad

154 craniospinal irradiation dose (median, 23.4 Gy), length of follow-up (mean, 4.3 years), and parental

155 ed ranges of 6.1-8.9 Gy (cortex) and 2.1-5.4 Gy (medulla).

156 Radiotherapy was delivered as 50.4 Gy (in 28 daily fractions of 1.8 Gy) in either 3D confor

157 definitive chemoradiation (median dose 50.4 Gy) followed by resection within 4 months.

158 e capecitabine-based chemoradiation (45-50.4 Gy) followed by six cycles of adjuvant capecitabine, bot

159 rbed radiation dose to tumor of 35.5 +/- 9.4 Gy and mean normal liver dose of 26.4 +/- 6.8 Gy.

160 GT3-Nano administered 24 h before or after 4 Gy of total-body irradiation (TBI) promoted rapid and co

161 4 genes one day after irradiation at 2 and 4 Gy, and comparing it with that of human blood irradiated

162 )Cs whole-body irradiation at a sublethal (4 Gy), a lethal (9 Gy), or a single high-dose administrati

163 0 Gy: RR, 4.24 [95% CI, 1.98 to 9.06]; 20-40 Gy: RR, 10.16 [95% CI, 5.18 to 19.94]; and >= 40 Gy: RR,

164 ment included external beam radiation (30-40 Gy) in 6 eyes, intravitreous melphalan (10-20 mug) in 4

165 st wall was reported for 98 of 986 (9.9%) 40 Gy patients, 155 (15.4%) of 1005 27 Gy patients, and 121

166 ,854 consenting patients (50 Gy, n = 937; 40 Gy, n = 917) were enrolled from 2009-2014 from eight cen

167 f ipsilateral breast tumour relapse after 40 Gy was 2.1% (1.4 to 3.1); estimated absolute differences

168 and the kidneys (BED(max) of 2 Gy(15) and 40 Gy(2.5), respectively) were assumed to be OARs.

169 We randomly allocated patients to either 40 Gy in 15 fractions (over 3 weeks), 27 Gy in five fractio

170 lapse; assuming a 2% 5-year incidence for 40 Gy, non-inferiority was predefined as <=1.6% excess for

171 radiation >= 34 Gy, abdominal radiation > 40 Gy, cisplatin >= 600 mg/m(2), amputation, or lung surger

172 RR, 10.16 [95% CI, 5.18 to 19.94]; and >= 40 Gy: RR, 19.48 [95% CI, 8.73 to 43.48]), having received

173 s designed to determine whether a dose of 40 Gy in 15 fr does not increase the occurrence of breast i

174 1 week is non-inferior to the standard of 40 Gy in 15 fractions over 3 weeks for local tumour control

175 apy at a dose of either 50 Gy in 25 fr or 40 Gy in 15 fr.

176 event occurred in 79 patients (31 in the 40 Gy group, 27 in the 27 Gy group, and 21 in the 26 Gy gro

177 entres, of whom 1361 were assigned to the 40 Gy schedule, 1367 to the 27 Gy schedule, and 1368 to the

178 nsurethral resection and induction CRT to 40 Gy.

179 ormal tissue effect risk for 27 Gy versus 40 Gy but not for 26 Gy versus 40 Gy.

180 1); estimated absolute differences versus 40 Gy in 15 fractions were -0.3% (-1.0 to 0.9) for 27 Gy in

181 p, and 21 in the 26 Gy group); HRs versus 40 Gy in 15 fractions were 0.86 (95% CI 0.51 to 1.44) for 2

182 sments from 1-5 years, odds ratios versus 40 Gy in 15 fractions were 1.55 (95% CI 1.32 to 1.83, p<0.0

183 Gy versus 40 Gy but not for 26 Gy versus 40 Gy.

184 erior five-fraction schedule: p=0.0022 vs 40 Gy in 15 fractions) and -0.7% (-1.3 to 0.3) for 26 Gy in

185 for 26 Gy in five fractions (p=0.00019 vs 40 Gy in 15 fractions).

186 er no difference or better outcome in the 40-Gy cohort compared with the 50-Gy cohort.

187 up and 3.0% (95% CI, 1.9% to 4.5%) in the 40-Gy group (risk difference, -0.3%; 95% CI, -2.3% to 1.7%)

188 p and 9.0% (95% CI, 7.2% to 11.1%) in the 40-Gy group (risk difference, -2.7%; 95% CI, -5.6% to 0.2%;

189 and 93.4% (95% CI, 91.0% to 95.2%) in the 40-Gy group.

190 ith similar or less frequent rates in the 40-Gy group.

191 ases who underwent radiation treatment 30-42 Gy in 3 Gy/fraction regimens to surgical cavity were ret

192 ED metrics yielding 50% TCP were 292 and 441 Gy, respectively.

193 uvant chemoradiotherapy (chemotherapy and 45 Gy radiotherapy, then surgery and radiotherapy boost bas

194 per dose intravenously on days 1-2) with 45 Gy preoperative radiotherapy, followed by surgical resec

195 s starting 3 days before 3 x 2 Gy or 4 x 0.5 Gy whole-body or tumor-focused radiation.

196 )Co gamma irradiation (~0.6 Gy/min, 7.5-12.5 Gy).

197 ence interval: 1.5%, 3.8%) for K(a,r) of 2-5 Gy and 4.5% (95% confidence interval: 1.5%, 7.6%) for K(

198 0% in 2017 for procedures with K(a,r) of 2-5 Gy and from 1.0% in 2010 to 0.13% in 2017 for procedures

199 igned to 50 Gy/25 fr (5 weeks) or 30 or 28.5 Gy in 5 once-weekly fr of 6.0 or 5.7 Gy.

200 22 (95% CI, 0.87 to 1.72; P = .248) for 28.5 Gy versus 50 Gy.

201 10 (95% CI, 0.70 to 1.71; P = .686) for 28.5 Gy versus 50 Gy.

202 gnificant difference in NTE rates after 28.5 Gy/5 fr compared with 50 Gy/25 fr, but NTE were higher a

203 4) and 96 deaths (50 Gy: 30; 30 Gy: 33; 28.5 Gy: 33) have occurred.

204 east cancer events (50 Gy: 3; 30 Gy: 4; 28.5 Gy: 4) and 96 deaths (50 Gy: 30; 30 Gy: 33; 28.5 Gy: 33)

205 delivered as 34 Gy of brachytherapy or 38.5 Gy of external bream radiation therapy in 10 fractions,

206 fractionated whole breast radiotherapy (42.5 Gy in 16 fractions over 3.5 weeks).

207 status, planned radiotherapy schedule (52.5 Gy in 20 fractions or 66 Gy in 33 fractions), and centre

208 responses during each of the 5 fractions (5 Gy per fraction), delivered from a clinical linear accel

209 ng 240 procedures with K(a,r) greater than 5 Gy, 22 had K(a,r) greater than 9 Gy.

210 ncreased cholesterol levels in response to 5 Gy X-rays.

211 7.6%) for K(a,r) greater than or equal to 5 Gy.

212 dures with K(a,r) greater than or equal to 5 Gy.

213 blasts, and ATM-deficient fibroblasts with 5 Gy X-rays and perform Hi-C at 30 minutes, 24 hours, or 5

214 or lower rectum who had received RCT (45-50 Gy with 5-fluorouracil or capecitabine) were included an

215 in 5 once-daily fractions (APBI arm) and 50 Gy in 25 fractions with a tumor bed boost (WBI arm) afte

216 : 3; 30 Gy: 4; 28.5 Gy: 4) and 96 deaths (50 Gy: 30; 30 Gy: 33; 28.5 Gy: 33) have occurred.

217 igned to radiotherapy at a dose of either 50 Gy in 25 fr or 40 Gy in 15 fr.

218 -up, 11 ipsilateral breast cancer events (50 Gy: 3; 30 Gy: 4; 28.5 Gy: 4) and 96 deaths (50 Gy: 30; 3

219 ration at 3 years compared with a dose of 50 Gy in 25 fr.

220 herapy for early breast cancer, a dose of 50 Gy in 25 fractions (fr) has been the standard regimen us

221 on was delivered in 25 daily fractions of 50 Gy over 5 weeks, with or without a supplemental boost to

222 A total of 1,854 consenting patients (50 Gy, n = 937; 40 Gy, n = 917) were enrolled from 2009-201

223 g conventional whole breast radiotherapy (50 Gy in 25 fractions over 5 weeks) versus hypofractionated

224 oma (pT1-2 pN0) were randomly assigned to 50 Gy/25 fr (5 weeks) or 30 or 28.5 Gy in 5 once-weekly fr

225 .87 to 1.72; P = .248) for 28.5 Gy versus 50 Gy.

226 .70 to 1.71; P = .686) for 28.5 Gy versus 50 Gy.

227 TE rates after 28.5 Gy/5 fr compared with 50 Gy/25 fr, but NTE were higher after 30 Gy/5 fr.

228 30 Gy) estimated to be isoeffective with 50 Gy/25 fr.

229 ome in the 40-Gy cohort compared with the 50-Gy cohort.

230 ce was 3.3% (95% CI, 2.0% to 5.0%) in the 50-Gy group and 3.0% (95% CI, 1.9% to 4.5%) in the 40-Gy gr

231 were 11.8% (95% CI, 9.7% to 14.1%) in the 50-Gy group and 9.0% (95% CI, 7.2% to 11.1%) in the 40-Gy g

232 was 93.4% (95% CI, 91.1% to 95.1%) in the 50-Gy group and 93.4% (95% CI, 91.0% to 95.2%) in the 40-Gy

233 aract, and the volume of retina receiving 52 Gy was associated with the risk of retinal detachment.

234 nchyma-absorbed dose was 37 Gy (range, 12-55 Gy).

235 Doses of 40 and 55 Gy caused slowing and interruption of cardiac impulse pr

236 Doses of 30, 40, and 55 Gy were delivered during expiration to the atrioventricu

237 90 Gy and a parenchymal dose of less than 55 Gy.

238 strain using (60)Co gamma irradiation (~0.6 Gy/min, 7.5-12.5 Gy).

239 calculated nominal absorbed doses of 7.8/1.6 Gy (cortex/medulla), SPECT/CT-based voxel-level dosimetr

240 ulated nominal absorbed doses of 7.8 and 1.6 Gy (in the cortex and medulla, respectively), SPECT/CT-b

241 e dose delivered to the target was up to 1.6 Gy, delivered with few hundreds of shots, limited by sec

242 Patients received 21.6 Gy to the preoperative primary tumor volume.

243 ch all patients received single SCT and 21.6 Gy without a boost.

244 The median dose of cRT was 30.6 Gy (range, 24-36 Gy).

245 in mean absorbed doses ranging from 3.0-6.6 Gy (cortex) and 2.7-5.1 Gy (medulla).

246 y resulted in mean absorbed doses of 3.0-6.6 Gy (cortex) and 2.7-5.1 Gy (medulla).

247 gamma-irradiation at doses of 0, 2, 4, or 6 Gy by colony formation assay.

248 y matter at 100 Gy and in white matter at 60 Gy.

249 -intensified chemoradiotherapy regimen of 60 Gy intensity-modulated radiotherapy with concurrent low-

250 RTOG 0617 compared standard-dose (SD; 60 Gy) versus high-dose (HD; 74 Gy) radiation with concurre

251 A 60-Gy radiation dose with concurrent chemotherapy should re

252 (78 Gy in 39 fractions over 7.8 weeks or 62 Gy in 20 fractions over 4 weeks, respectively) or stereo

253 rapy schedule (52.5 Gy in 20 fractions or 66 Gy in 33 fractions), and centre.

254 etermine if dose de-escalation from 60 to 66 Gy to 30 to 36 Gy of adjuvant radiotherapy (RT) for sele

255 ter and depth) at a single pulse dose of 0.7 Gy via multi-energy slice selection from the broad input

256 estimate for photographic end point was 2.7 Gy (95% CI, 1.5 to 3.9 Gy), giving a 5-fr schedule of 28

257 or 28.5 Gy in 5 once-weekly fr of 6.0 or 5.7 Gy.

258 pression were shown in MLN-M isolated from 7 Gy GIARS mice treated with GL, and these macrophages did

259 tion and subsequent sepsis were minimal in 7 Gy GIARS mice treated with GL.

260 ate that gut bacteria-associated sepsis in 7 Gy GIARS mice was controlled by the GL through the inhib

261 M2bM survival, is silenced in the MLNs of 7 Gy GIARS mice because of Gas5 RNA, which is increased in

262 ity of mice exposed to 7 Gy of gamma-rays (7 Gy GIARS mice) was completely controlled after the admin

263 is study, the mortality of mice exposed to 7 Gy of gamma-rays (7 Gy GIARS mice) was completely contro

264 ompleted the full planned treatment dose (70 Gy) of radiotherapy without any delays >= 5 days; 88.1%

265 rd-dose (SD; 60 Gy) versus high-dose (HD; 74 Gy) radiation with concurrent chemotherapy and determine

266 Mice were exposed to a lethal dose (9.75 Gy) of Cobalt-60 gamma radiation and euthanized at four

267 e control +/- ablative RT to a cumulative 75 Gy administered in 15 daily fractions to a limited tumor

268 were randomly assigned to receive C-IMRT (76 Gy in 38 fractions) or H-IMRT (70.2 Gy in 26 fractions).

269 moderately hypofractionated radiotherapy (78 Gy in 39 fractions over 7.8 weeks or 62 Gy in 20 fractio

270 red as 50.4 Gy (in 28 daily fractions of 1.8 Gy) in either 3D conformal radiotherapy or intensity mod

271 noma absorbed dose ranges from 30.3 to 127.8 Gy.

272 ation with fractionated irradiation (5 x 4.8 Gy).

273 doses for response were 48.3, 48.8, and 41.8 Gy, respectively.

274 y), chemoradiotherapy (chemotherapy and 55.8 Gy radiotherapy), and neoadjuvant chemoradiotherapy (che

275 roups were surgery alone, radiotherapy (55.8 Gy), chemoradiotherapy (chemotherapy and 55.8 Gy radioth

276 y and mean normal liver dose of 26.4 +/- 6.8 Gy.

277 total body irradiation (TBI), 2 Gy of TBI, 8 Gy of TBI, or no conditioning and treated by using trans

278 se induction, or with (2) irradiation (3 x 8 Gy), (3) cyclophosphamide, (4) cisplatin or (5) doxorubi

279 ls with extranodal extension to 36 Gy in 1.8-Gy fractions twice per day.

280 sease (median, 121 Gy [IQR: 86-190 Gy] vs 85 Gy [IQR: 58-164 Gy]; P = .02).

281 iles, 0.18-0.75; dual-energy VNC CT) to 0.89 Gy (5th-95th percentiles, 0.42-1.0; three-phase CT).

282 hic end point was 2.7 Gy (95% CI, 1.5 to 3.9 Gy), giving a 5-fr schedule of 28 Gy (95% CI, 26 to 30 G

283 high mortality rates in mice exposed to 6-9 Gy of gamma-rays.

284 PETPVC led to improved ranges of 6.1-8.9 Gy (cortex) and 2.1-5.4 Gy (medulla).

285 reased 30-day survival of CD2F1 mice after 9 Gy TBI 12.5-25% compared with the vehicle control treate

286 roaches in the adult mouse brain following 9 Gy cranial RT.

287 an ameliorate cognitive deficits following 9 Gy head-only irradiation.

288 radiation at a sublethal (4 Gy), a lethal (9 Gy), or a single high-dose administration of (153)Sm-eth

289 Using a clinically relevant 9 Gy irradiation paradigm, we exposed mice to cranial (hea

290 weeks) or nivolumab (same dose) plus SBRT (9 Gy x 3) to 1 lesion.

291 ater than 5 Gy, 22 had K(a,r) greater than 9 Gy.

292 ng 90% survival at 50 mg/kg against lethal 9-Gy TBI.

293 h a mean tumor-absorbed dose of less than 90 Gy (hazard ratio, 0.16; 95% CI, 0.06-0.511).

294 g a mean tumor-absorbed dose of more than 90 Gy and a parenchymal dose of less than 55 Gy.

295 h a mean tumor-absorbed dose of more than 90 Gy was significantly better than for patients with a mea

296 ated total absorbed dose to the BM was 0.992 Gy for all patients (range, 0.431-2.323 Gy).

297 t), the mean difference in parenchymal dose (Gy) per step increase in CTCAE grade category was 5.75 (

298 X-ray imaging with sensitivity up to 173 muC Gy(air) (-1) cm(-2) .

299 PSCs exhibit high sensitivity of 1652.3 muC Gy(air)(-1) cm(-2) and very low detectable dose rate of

300 cm(2) /V and an X-ray sensitivity of 207 muC.Gy(-1).cm(-2).